Table 2 IPA in non-liver transplant patients with critical liver diseases. (CSID: Chinese Society for Infectious Diseases. CSH: Chinese Society for Hepatology. CSCC: Chinese Society for Critical Care. Cas: Caspofungin. Vor: Voriconazole).
Author (year) | Ref | liver diseases | ACLF criteria | IPA criteria | IPA Incidence | Transplant-free Mortality | Anti-fungal treatments Cas/Vor/others |
|---|---|---|---|---|---|---|---|
Wang, 2010 | HBV ACLF | CSID/CSH | EORTC/MSG | 66/798 (8.3%) | 100% (30 days) | C43/V0/0 | |
Wu, 2012 | HBV ACLF | APASL | EORTC/MSG | 29/470 (6.1%) | 86.2% (in hospital) | C0/V29/0 | |
Chen, 2013 | HBV ACLF | APASL | EORTC/MSG | 39/787 (5%) | 94.8% (90 days) | C10/V9/20 others | |
Gustot, 2014 | Alcoholic hepatitis | — | EORTC/MSG | 13/94 (13.8%) | 100% (40 days) | C6/V2/6 others | |
Falcone, 2011 | Critical liver disorders | — | EORTC/MSG | — | 48/67 (71.6%) | C13/V5/30 others | |
Zhao, 2011 | HBV ACLF | CSID/CSH | CSCC 2007 | 83/681 (12.1%) | 73.49% (in hospital) | C0/V0/others | |
Zou, 2012 | HBV ACLF | CSID/CSH | EORTC/MSG | 39/967 (4%) | 79.5% (30 days) | C6/V0/others | |
Liu, 2013 | HBV ACLF | CSID/CSH | EORTC/MSG | 20/463 (4.3%) | 75% (in hospital) | C0/V5/others |
